Hematopoietic stem cells for severe Crohn's disease

The aim of this study is to assess the safety and feasibility of autologous peripheral hematopoietic stem cell transplantation in patients with severe Crohn's disease, following patient conditioning with high-dose cyclophosphamide and anti-thymocyte globulin. The transplantation was safe and resulted in treatment-free remissions for as long as 5 years, and remission rates of 70-80% for 5 years.